ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER

被引：0
|
作者：
Farhat, Fadi [3 ]
Kattan, Joseph [2 ]
Ghosn, Marwan [1 ]
机构：
[1] St Joseph Univ, Fac Med, Hematol Oncol, Beirut, Lebanon
[2] Hotel Dieu France Univ Hosp, Hematol Oncol, Beirut, Lebanon
[3] Lebanese Univ, Hematol Oncol, Beirut, Lebanon
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)30073-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO61
引用
收藏
页码：S42 / S43
页数：5
相关论文
共 50 条
  • [21] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Carlos Acevedo-Gadea
    Christos Hatzis
    Gina Chung
    Neal Fishbach
    Kimberly Lezon-Geyda
    Daniel Zelterman
    Michael P. DiGiovanna
    Lyndsay Harris
    Maysa M. Abu-Khalaf
    Breast Cancer Research and Treatment, 2015, 150 : 157 - 167
  • [22] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Yanagi, Hiroyo
    Kobayashi, Kokoro
    Shibayama, Tomoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ohno, Shinji
    Ito, Yoshinori
    BREAST, 2017, 35 : 78 - 84
  • [23] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Acevedo-Gadea, Carlos
    Hatzis, Christos
    Chung, Gina
    Fishbach, Neal
    Lezon-Geyda, Kimberly
    Zelterman, Daniel
    DiGiovanna, Michael P.
    Harris, Lyndsay
    Abu-Khalaf, Maysa M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 157 - 167
  • [24] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [26] First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Goedhalss, L.
    Gil, M. Gil
    Bernardoe, G.
    Villanova, G.
    Tubiana-Mathieu, N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 220 - 221
  • [27] Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+ MBC) (pts).
    Chan, A
    Petruzelka, L
    Untch, M
    Martin, M
    Gil, MG
    Porta, VG
    Wojtukiewicz, MZ
    Stewart, A
    Aubert, D
    Gasmi, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 25S - 25S
  • [28] A multicenter study of trastuzumab N and vinorelbine (N) as first and second line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+ MBC).
    Franquesa, RM
    Centelles, M
    Villadiego, K
    Janáriz, J
    Arcusa, A
    Cirera, L
    Segui, M
    Saigi, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 94S - 94S
  • [29] The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced HER2-positive breast cancer
    Esfahani, K.
    Ferrario, C.
    Le, P.
    Panasci, L.
    CURRENT ONCOLOGY, 2014, 21 (05) : E723 - E727
  • [30] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
12345